NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price, Forecast & News

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its quarterly earnings results on Tuesday, February, 25th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.12 by $0.04. The biopharmaceutical company had revenue of $60.93 million for the quarter, compared to analyst estimates of $59.77 million. Vanda Pharmaceuticals had a net margin of 50.86% and a return on equity of 35.52%. View Vanda Pharmaceuticals' Earnings History.

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for Vanda Pharmaceuticals.

Vanda Pharmaceuticals updated its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $240-260 million, compared to the consensus revenue estimate of $274.55 million.

4 equities research analysts have issued 12-month price objectives for Vanda Pharmaceuticals' stock. Their forecasts range from $12.00 to $25.00. On average, they expect Vanda Pharmaceuticals' share price to reach $17.25 in the next twelve months. This suggests a possible upside of 56.8% from the stock's current price. View Analyst Price Targets for Vanda Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vanda Pharmaceuticals.

Press coverage about VNDA stock has trended extremely negative recently, according to InfoTrie. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vanda Pharmaceuticals earned a media sentiment score of -4.4 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Vanda Pharmaceuticals.

Vanda Pharmaceuticals saw a increase in short interest in February. As of February 14th, there was short interest totalling 4,490,000 shares, an increase of 9.8% from the January 30th total of 4,090,000 shares. Based on an average daily trading volume, of 544,600 shares, the short-interest ratio is presently 8.2 days. Currently, 8.7% of the shares of the company are sold short. View Vanda Pharmaceuticals' Current Options Chain.

Some companies that are related to Vanda Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Array Biopharma (ARRY), Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Crispr Therapeutics (CRSP) and ImmunoGen (IMGN).

Vanda Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Palo Alto Investors LP (8.48%), Renaissance Technologies LLC (6.47%), State Street Corp (4.75%), Prudential Financial Inc. (2.37%), Acadian Asset Management LLC (1.85%) and Geode Capital Management LLC (1.43%). Company insiders that own Vanda Pharmaceuticals stock include Gian Piero Reverberi, Gunther Birznieks, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams. View Institutional Ownership Trends for Vanda Pharmaceuticals.

VNDA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Goldman Sachs Group Inc., FMR LLC, Charles Schwab Investment Management Inc., Rafferty Asset Management LLC, 361 Capital LLC, Pictet Asset Management Ltd. and Palo Alto Investors LP. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gian Piero Reverberi, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams. View Insider Buying and Selling for Vanda Pharmaceuticals.

VNDA stock was acquired by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Renaissance Technologies LLC, Bank of Montreal Can, Acadian Asset Management LLC, Man Group plc and Panagora Asset Management Inc.. View Insider Buying and Selling for Vanda Pharmaceuticals.

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VNDA stock can currently be purchased for approximately $11.00.

Vanda Pharmaceuticals has a market capitalization of $586.71 million and generates $227.19 million in revenue each year. The biopharmaceutical company earns $25.20 million in net income (profit) each year or $2.11 on an earnings per share basis. Vanda Pharmaceuticals employs 270 workers across the globe.View Additional Information About Vanda Pharmaceuticals.

The official website for Vanda Pharmaceuticals is http://www.vandapharma.com/.

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]